AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions. Its research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology to treat atrial fibrillation with lasting solutions. Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. AtriCure also pioneered the AtriClip LAA Exclusion System. The company collaborates with surgeons to make surgeries like the Maze IV simpler to perform and be reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, AtriCure is working to reduce the global atrial fibrillation epidemic.
Company Growth (employees)
Type
Public
HQ
Mason, US
Founded
2000
Size (employees)
500 (est)
AtriCure was founded in 2000 and is headquartered in Mason, US

Key People at AtriCure

Michael Carrel

Michael Carrel

President & CEO
Andrew Wade

Andrew Wade

VP & CFO

AtriCure Office Locations

AtriCure has offices in Mason, West Chester, Minnetonka, San Ramon and in 28 other locations
Mason, US (HQ)
7555 Innovation Way
Amsterdam-Zuidoost, NL
260 De Entree
San Ramon, US
110 2420 Camino Ramon
Minnetonka, US
250 130 Cheshire Ln
West Chester, US
6217 Centre Park Drive
Show all (32)

AtriCure Data and Metrics

AtriCure Financial Metrics

AtriCure's revenue was reported to be $41.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

41.3 m

Gross profit (Q1, 2017)

30 m

Gross profit margin (Q1, 2017), %

73%

Net income (Q1, 2017)

(10.2 m)

EBIT (Q1, 2017)

(9.6 m)

Market capitalization (22-Sep-2017)

710 m

Cash (31-Mar-2017)

19.2 m
AtriCure's current market capitalization is $710 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

81.9 m107.5 m129.8 m155.1 m

Revenue growth, %

31%21%20%

Cost of goods sold

22.3 m31.7 m36.9 m44 m

Gross profit

59.6 m75.8 m92.9 m111.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

26.5 m26.7 m29.9 m32.6 m31.4 m35.9 m39.7 m38.3 m41.3 m

Cost of goods sold

7.7 m7.8 m8.2 m9.5 m8.9 m10 m10.9 m10.9 m11.3 m

Gross profit

18.8 m18.9 m21.7 m23.1 m22.5 m25.9 m28.8 m27.5 m30 m

Gross profit Margin, %

71%71%73%71%72%72%73%72%73%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

14.9 m28.4 m23.8 m24.2 m

Inventories

10.2 m14.3 m17.7 m17.7 m

Current Assets

52.5 m93.5 m74.8 m85.7 m

PP&E

5.6 m11.6 m31.3 m30 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

42 m35.5 m23.6 m30 m28.7 m20.8 m19.9 m16.1 m19.2 m

Inventories

12.7 m14.6 m15.1 m16.1 m16.6 m19 m19.3 m19 m18.8 m

Current Assets

92.8 m90.7 m93.4 m90.7 m84.1 m65.4 m86.5 m84.4 m79.1 m

PP&E

6.5 m9.8 m13.9 m19.4 m27.5 m31.2 m30.9 m30.7 m29.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(11.5 m)(16.2 m)(27.2 m)(33.3 m)

Depreciation and Amortization

2 m4.8 m6.3 m9.3 m

Accounts Receivable

(1.2 m)(4.2 m)(900 k)(2 m)

Inventories

(2.3 m)(4.3 m)(3 m)(79 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.7 m)(466 k)(5.3 m)(4.9 m)(6.1 m)(9.7 m)(8.2 m)(6.8 m)(10.2 m)

Inventories

12.7 m14.6 m15.1 m16.1 m16.6 m19 m19.3 m19 m18.8 m

Accounts Payable

7.5 m7.8 m9.7 m9.3 m11.2 m12.8 m11.9 m11 m11.3 m
USDY, 2017

Revenue/Employee

82.5 k

Financial Leverage

1.7 x
Show all financial metrics

AtriCure Market Value History

AtriCure Job Categories

Traffic Overview of AtriCure

AtriCure Online and Social Media Presence

AtriCure Company Life and Culture

You may also be interested in